Arcus Biosciences (NYSE:RCUS) President Sells $245,603.00 in Stock

by · The Cerbat Gem

Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) President Juan Jaen sold 11,225 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $245,603.00. Following the completion of the sale, the president directly owned 355,995 shares in the company, valued at $7,789,170.60. This represents a 3.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Arcus Biosciences Stock Performance

Shares of RCUS traded down $0.26 during midday trading on Thursday, hitting $22.02. 1,175,874 shares of the stock traded hands, compared to its average volume of 1,200,446. The business’s 50 day moving average price is $20.82 and its two-hundred day moving average price is $13.98. The firm has a market capitalization of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $26.40.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The business had revenue of $26.00 million for the quarter, compared to analysts’ expectations of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The company’s revenue for the quarter was down 45.8% compared to the same quarter last year. During the same quarter last year, the company earned ($1.00) EPS. Equities research analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RCUS has been the subject of several analyst reports. Bank of America boosted their price objective on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Citigroup reissued a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a research note on Monday. HC Wainwright upped their price objective on shares of Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Wedbush set a $35.00 target price on shares of Arcus Biosciences and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $28.89.

Get Our Latest Analysis on Arcus Biosciences

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its position in Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after acquiring an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after purchasing an additional 2,845 shares in the last quarter. CWM LLC lifted its stake in Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after purchasing an additional 3,810 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Arcus Biosciences by 34.3% during the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock worth $57,000 after buying an additional 1,796 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in Arcus Biosciences by 440.3% during the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after buying an additional 6,191 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Recommended Stories